Breaking News

Wednesday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Ideaya Biosciences management to meet virtually with Oppenheimer » 04:55
07/01/20
07/01
04:55
07/01/20
04:55
IDYA

Ideaya Biosciences

$14.20 /

+0.97 (+7.33%)

Virtual Meeting to be…

Virtual Meeting to be held on July 1 hosted by Oppenheimer.

ShowHide Related Items >><<
IDYA Ideaya Biosciences
$14.20 /

+0.97 (+7.33%)

IDYA Ideaya Biosciences
$14.20 /

+0.97 (+7.33%)

06/17/20 H.C. Wainwright
Ideaya Biosciences price target raised to $22 from $13 at H.C. Wainwright
06/16/20 Roth Capital
Ideaya Biosciences price target raised to $23 from $12 at Roth Capital
06/16/20 Oppenheimer
Ideaya Biosciences price target raised to $25 from $17 at Oppenheimer
04/06/20
Fly Intel: Top five analyst initiations
IDYA Ideaya Biosciences
$14.20 /

+0.97 (+7.33%)

  • 18
    Jun
IDYA Ideaya Biosciences
$14.20 /

+0.97 (+7.33%)

Over a week ago
Conference/Events
Ideaya Biosciences management to meet virtually with Oppenheimer » 09:01
06/26/20
06/26
09:01
06/26/20
09:01
IDYA

Ideaya Biosciences

$14.76 /

+0.27 (+1.86%)

Virtual Meeting to be…

Virtual Meeting to be held on July 1 hosted by Oppenheimer.

ShowHide Related Items >><<
IDYA Ideaya Biosciences
$14.76 /

+0.27 (+1.86%)

IDYA Ideaya Biosciences
$14.76 /

+0.27 (+1.86%)

06/17/20 H.C. Wainwright
Ideaya Biosciences price target raised to $22 from $13 at H.C. Wainwright
06/16/20 Roth Capital
Ideaya Biosciences price target raised to $23 from $12 at Roth Capital
06/16/20 Oppenheimer
Ideaya Biosciences price target raised to $25 from $17 at Oppenheimer
04/06/20
Fly Intel: Top five analyst initiations
IDYA Ideaya Biosciences
$14.76 /

+0.27 (+1.86%)

  • 18
    Jun
IDYA Ideaya Biosciences
$14.76 /

+0.27 (+1.86%)

Syndicate
Ideaya Biosciences 6.677M share Secondary priced at $15.00 » 21:38
06/17/20
06/17
21:38
06/17/20
21:38
IDYA

Ideaya Biosciences

$18.73 /

+5.62 (+42.87%)

The deal size was…

The deal size was increased to $100M in common stock from $60M in common stock. JPMorgan, Citi and Jefferies acted as joint book running managers for the offering.

ShowHide Related Items >><<
IDYA Ideaya Biosciences
$18.73 /

+5.62 (+42.87%)

IDYA Ideaya Biosciences
$18.73 /

+5.62 (+42.87%)

06/17/20 H.C. Wainwright
Ideaya Biosciences price target raised to $22 from $13 at H.C. Wainwright
06/16/20 Roth Capital
Ideaya Biosciences price target raised to $23 from $12 at Roth Capital
06/16/20 Oppenheimer
Ideaya Biosciences price target raised to $25 from $17 at Oppenheimer
04/06/20
Fly Intel: Top five analyst initiations
IDYA Ideaya Biosciences
$18.73 /

+5.62 (+42.87%)

  • 18
    Jun
IDYA Ideaya Biosciences
$18.73 /

+5.62 (+42.87%)

Recommendations
Ideaya Biosciences price target raised to $22 from $13 at H.C. Wainwright » 06:16
06/17/20
06/17
06:16
06/17/20
06:16
IDYA

Ideaya Biosciences

$13.11 /

+4.12 (+45.83%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Edward White raised the firm's price target on Ideaya Biosciences (IDYA) to $22 from $13 and reiterates a Buy rating on the shares after the company announced a "broad" partnership for its synthetic lethality programs with GlaxoSmithKline (GSK).

ShowHide Related Items >><<
IDYA Ideaya Biosciences
$13.11 /

+4.12 (+45.83%)

IDYA Ideaya Biosciences
$13.11 /

+4.12 (+45.83%)

06/16/20 Roth Capital
Ideaya Biosciences price target raised to $23 from $12 at Roth Capital
06/16/20 Oppenheimer
Ideaya Biosciences price target raised to $25 from $17 at Oppenheimer
04/06/20
Fly Intel: Top five analyst initiations
04/06/20 H.C. Wainwright
Ideaya Biosciences initiated with a Buy at H.C. Wainwright
IDYA Ideaya Biosciences
$13.11 /

+4.12 (+45.83%)

  • 18
    Jun
IDYA Ideaya Biosciences
$13.11 /

+4.12 (+45.83%)

Recommendations
Ideaya Biosciences price target raised to $23 from $12 at Roth Capital » 16:54
06/16/20
06/16
16:54
06/16/20
16:54
IDYA

Ideaya Biosciences

$13.11 /

+4.12 (+45.83%)

, GSK

GlaxoSmithKline

$41.31 /

+0.585 (+1.44%)

Roth Capital analyst…

Roth Capital analyst Zegbeh Jallah raised the firm's price target on Ideaya Biosciences (IDYA) to $23 from $12 and keeps a Buy rating on the shares after the company entered into a strategic partnership in Synthetic Lethality with GlaxoSmithKline (GSK). The "unprecedented for preclinical assets" partnership is valued at over $3B and serves to validate Ideaya's platform, the analyst tells investors in a research note. The company's programs could "accelerate more rapidly given GlaxoSmithKline's "expertise in synthetic lethality and protein degradation for Oncology indications", Jallah adds.

ShowHide Related Items >><<
IDYA Ideaya Biosciences
$13.11 /

+4.12 (+45.83%)

GSK GlaxoSmithKline
$41.31 /

+0.585 (+1.44%)

IDYA Ideaya Biosciences
$13.11 /

+4.12 (+45.83%)

06/16/20 Oppenheimer
Ideaya Biosciences price target raised to $25 from $17 at Oppenheimer
04/06/20
Fly Intel: Top five analyst initiations
04/06/20 H.C. Wainwright
Ideaya Biosciences initiated with a Buy at H.C. Wainwright
03/13/20
Fly Intel: Top analyst initiations
GSK GlaxoSmithKline
$41.31 /

+0.585 (+1.44%)

05/14/20 UBS
GlaxoSmithKline price target raised to 1,920 GBp from 1,900 GBp at UBS
05/05/20 JPMorgan
GlaxoSmithKline price target lowered to 1,700 GBp from 1,750 GBp at JPMorgan
04/30/20 Barclays
GlaxoSmithKline price target raised to 1,550 GBp from 1,450 GBp at Barclays
03/11/20 JPMorgan
JPMorgan backs Neutral on GSK after 2019 annual report
IDYA Ideaya Biosciences
$13.11 /

+4.12 (+45.83%)

GSK GlaxoSmithKline
$41.31 /

+0.585 (+1.44%)

  • 18
    Jun
GSK GlaxoSmithKline
$41.31 /

+0.585 (+1.44%)

IDYA Ideaya Biosciences
$13.11 /

+4.12 (+45.83%)

GSK GlaxoSmithKline
$41.31 /

+0.585 (+1.44%)

GSK GlaxoSmithKline
$41.31 /

+0.585 (+1.44%)

Syndicate
Ideaya Biosciences files to sell $60M in common stock » 16:02
06/16/20
06/16
16:02
06/16/20
16:02
IDYA

Ideaya Biosciences

$13.09 /

+4.1 (+45.61%)

J.P. Morgan, Citigroup…

J.P. Morgan, Citigroup and Jefferies are acting as joint book-running managers for the offering.

ShowHide Related Items >><<
IDYA Ideaya Biosciences
$13.09 /

+4.1 (+45.61%)

IDYA Ideaya Biosciences
$13.09 /

+4.1 (+45.61%)

06/16/20 Oppenheimer
Ideaya Biosciences price target raised to $25 from $17 at Oppenheimer
04/06/20
Fly Intel: Top five analyst initiations
04/06/20 H.C. Wainwright
Ideaya Biosciences initiated with a Buy at H.C. Wainwright
03/13/20
Fly Intel: Top analyst initiations
IDYA Ideaya Biosciences
$13.09 /

+4.1 (+45.61%)

IDYA Ideaya Biosciences
$13.09 /

+4.1 (+45.61%)

Recommendations
Ideaya Biosciences price target raised to $25 from $17 at Oppenheimer » 11:20
06/16/20
06/16
11:20
06/16/20
11:20
IDYA

Ideaya Biosciences

$11.45 /

+2.46 (+27.36%)

Oppenheimer analyst Kevin…

Oppenheimer analyst Kevin DeGeeter raised the firm's price target on Ideaya Biosciences (IDYA) to $25 from $17 and keeps an Outperform rating on the shares after the company and GlaxoSmithKline (GSK) announced a strategic partnership that includes Ideaya's Synthetic Lethality programs MAT2A, Pol Theta, and Werner Helicase programs.

ShowHide Related Items >><<
IDYA Ideaya Biosciences
$11.45 /

+2.46 (+27.36%)

IDYA Ideaya Biosciences
$11.45 /

+2.46 (+27.36%)

04/06/20
Fly Intel: Top five analyst initiations
04/06/20 H.C. Wainwright
Ideaya Biosciences initiated with a Buy at H.C. Wainwright
03/13/20
Fly Intel: Top analyst initiations
03/13/20 Roth Capital
Ideaya Biosciences initiated with a Buy at Roth Capital
IDYA Ideaya Biosciences
$11.45 /

+2.46 (+27.36%)

IDYA Ideaya Biosciences
$11.45 /

+2.46 (+27.36%)

On The Fly
Fly Intel: Pre-market Movers » 09:01
06/16/20
06/16
09:01
06/16/20
09:01
LLY

Eli Lilly

$141.46 /

-2.27 (-1.58%)

, HEAR

Turtle Beach

$11.66 /

+0.37 (+3.28%)

, IDYA

Ideaya Biosciences

$8.99 /

+1 (+12.52%)

, GSK

GlaxoSmithKline

$40.73 /

+0.305 (+0.75%)

, MCD

McDonald's

$189.42 /

+0.36 (+0.19%)

, IQ

iQIYI

$19.15 /

+1.34 (+7.52%)

, ANVS

Annovis Bio

$4.48 /

+0.17 (+3.94%)

, SNY

Sanofi

$50.57 /

+0.53 (+1.06%)

, NPTN

NeoPhotonics

$9.47 /

+0.59 (+6.65%)

, IZEA

Izea

$1.87 /

+0.16 (+9.36%)

, AYI

Acuity Brands

$97.70 /

+0.08 (+0.08%)

Check out this morning's…

Open Full Text

ShowHide Related Items >><<
SNY Sanofi
$50.57 /

+0.53 (+1.06%)

NPTN NeoPhotonics
$9.47 /

+0.59 (+6.65%)

MCD McDonald's
$189.42 /

+0.36 (+0.19%)

LLY Eli Lilly
$141.46 /

-2.27 (-1.58%)

IZEA Izea
$1.87 /

+0.16 (+9.36%)

IQ iQIYI
$19.15 /

+1.34 (+7.52%)

IDYA Ideaya Biosciences
$8.99 /

+1 (+12.52%)

HEAR Turtle Beach
$11.66 /

+0.37 (+3.28%)

GSK GlaxoSmithKline
$40.73 /

+0.305 (+0.75%)

AYI Acuity Brands
$97.70 /

+0.08 (+0.08%)

ANVS Annovis Bio
$4.48 /

+0.17 (+3.94%)

LLY Eli Lilly
$141.46 /

-2.27 (-1.58%)

06/16/20 Guggenheim
Guggenheim upgrades Eli Lilly to Buy after 'transformational' breast cancer data
06/16/20 Guggenheim
Eli Lilly upgraded to Buy from Neutral at Guggenheim
06/05/20 Piper Sandler
Nektar sees 'encouraging trends' in early lupus trial, says Piper Sandler
06/02/20 JPMorgan
JPMorgan positions for second half with three picks in Major Pharma
HEAR Turtle Beach
$11.66 /

+0.37 (+3.28%)

05/08/20 Lake Street
Turtle Beach price target raised to $14 from $12 at Lake Street
04/29/20 Wedbush
Turtle Beach downgraded to Neutral at Wedbush as likely upside priced in
04/29/20 Wedbush
Turtle Beach downgraded to Neutral from Outperform at Wedbush
03/11/20 Oppenheimer
Turtle Beach price target lowered to $13 from $18 at Oppenheimer
IDYA Ideaya Biosciences
$8.99 /

+1 (+12.52%)

04/06/20
Fly Intel: Top five analyst initiations
04/06/20 H.C. Wainwright
Ideaya Biosciences initiated with a Buy at H.C. Wainwright
03/13/20
Fly Intel: Top analyst initiations
03/13/20 Roth Capital
Ideaya Biosciences initiated with a Buy at Roth Capital
GSK GlaxoSmithKline
$40.73 /

+0.305 (+0.75%)

05/14/20 UBS
GlaxoSmithKline price target raised to 1,920 GBp from 1,900 GBp at UBS
05/05/20 JPMorgan
GlaxoSmithKline price target lowered to 1,700 GBp from 1,750 GBp at JPMorgan
04/30/20 Barclays
GlaxoSmithKline price target raised to 1,550 GBp from 1,450 GBp at Barclays
03/11/20 JPMorgan
JPMorgan backs Neutral on GSK after 2019 annual report
MCD McDonald's
$189.42 /

+0.36 (+0.19%)

06/16/20 Stephens
McDonald's quarter-to-date comps tracking ahead of expectations, says Stephens
06/15/20 Kalinowski
McDonald's upgraded to Buy from Neutral at Kalinowski
06/09/20 BTIG
Beyond Meat's China distribution to accelerate sales in second half, says BTIG
05/26/20 JPMorgan
McDonald's price target raised to $180 from $172 at JPMorgan
IQ iQIYI
$19.15 /

+1.34 (+7.52%)

05/20/20 HSBC
iQIYI price target lowered to $23 from $32 at HSBC
04/14/20
Fly Intel: Top five analyst initiations
04/13/20 Oppenheimer
iQIYI initiated with an Outperform at Oppenheimer
04/09/20 Mizuho
Baidu concerns overstated, current valuation 'compelling,' says Mizuho
ANVS Annovis Bio
$4.48 /

+0.17 (+3.94%)

SNY Sanofi
$50.57 /

+0.53 (+1.06%)

06/12/20 Jefferies
Regeneron price target raised to $691 from $657 at Jefferies
06/10/20 Morgan Stanley
Denali shares to be under pressure after DNL747 decision, says Morgan Stanley
06/09/20 Morgan Stanley
Sanofi price target raised to EUR 107 from EUR 101 at Morgan Stanley
06/09/20 Citi
Amicus shares worth $10 on Galafold alone, says Citi
NPTN NeoPhotonics
$9.47 /

+0.59 (+6.65%)

06/16/20 B. Riley FBR
NeoPhotonics downgraded to Neutral on Huawei risks at B. Riley FBR
06/16/20 B. Riley FBR
NeoPhotonics downgraded to Neutral from Buy at B. Riley FBR
05/21/20 Rosenblatt
Rosenblatt sees little impact on Lumentum, NeoPhotonics' current sales to Huawei
05/01/20 Northland
NeoPhotonics price target raised to $13 from $9.75 at Northland
IZEA Izea
$1.87 /

+0.16 (+9.36%)

06/16/20 Ladenburg
Izea downgraded to Neutral from Buy at Ladenburg
05/15/20 Craig-Hallum
Izea downgraded to Hold from Buy at Craig-Hallum
05/15/20 Craig-Hallum
Izea downgraded to Hold from Buy at Craig-Hallum
AYI Acuity Brands
$97.70 /

+0.08 (+0.08%)

06/15/20 Goldman Sachs
Acuity Brands downgraded to Sell from Neutral at Goldman Sachs
06/09/20 JMP Securities
Acuity Brands downgraded to Market Perform from Outperform at JMP Securities
06/08/20 Oppenheimer
Acuity Brands upgraded to Outperform at Oppenheimer
06/08/20 Oppenheimer
Acuity Brands upgraded to Outperform from Perform at Oppenheimer
SNY Sanofi
$50.57 /

+0.53 (+1.06%)

NPTN NeoPhotonics
$9.47 /

+0.59 (+6.65%)

MCD McDonald's
$189.42 /

+0.36 (+0.19%)

LLY Eli Lilly
$141.46 /

-2.27 (-1.58%)

IZEA Izea
$1.87 /

+0.16 (+9.36%)

IQ iQIYI
$19.15 /

+1.34 (+7.52%)

IDYA Ideaya Biosciences
$8.99 /

+1 (+12.52%)

HEAR Turtle Beach
$11.66 /

+0.37 (+3.28%)

GSK GlaxoSmithKline
$40.73 /

+0.305 (+0.75%)

AYI Acuity Brands
$97.70 /

+0.08 (+0.08%)

SNY Sanofi
$50.57 /

+0.53 (+1.06%)

NPTN NeoPhotonics
$9.47 /

+0.59 (+6.65%)

MCD McDonald's
$189.42 /

+0.36 (+0.19%)

LLY Eli Lilly
$141.46 /

-2.27 (-1.58%)

IQ iQIYI
$19.15 /

+1.34 (+7.52%)

GSK GlaxoSmithKline
$40.73 /

+0.305 (+0.75%)

SNY Sanofi
$50.57 /

+0.53 (+1.06%)

NPTN NeoPhotonics
$9.47 /

+0.59 (+6.65%)

MCD McDonald's
$189.42 /

+0.36 (+0.19%)

LLY Eli Lilly
$141.46 /

-2.27 (-1.58%)

IQ iQIYI
$19.15 /

+1.34 (+7.52%)

IDYA Ideaya Biosciences
$8.99 /

+1 (+12.52%)

HEAR Turtle Beach
$11.66 /

+0.37 (+3.28%)

GSK GlaxoSmithKline
$40.73 /

+0.305 (+0.75%)

AYI Acuity Brands
$97.70 /

+0.08 (+0.08%)

ANVS Annovis Bio
$4.48 /

+0.17 (+3.94%)

SNY Sanofi
$50.57 /

+0.53 (+1.06%)

MCD McDonald's
$189.42 /

+0.36 (+0.19%)

IQ iQIYI
$19.15 /

+1.34 (+7.52%)

GSK GlaxoSmithKline
$40.73 /

+0.305 (+0.75%)

Hot Stocks
Ideaya Biosciences, GlaxoSmithKline announce Synthetic Lethality partnership » 06:06
06/16/20
06/16
06:06
06/16/20
06:06
IDYA

Ideaya Biosciences

$8.99 /

+1 (+12.52%)

, GSK

GlaxoSmithKline

$40.73 /

+0.305 (+0.75%)

Ideaya Biosciences (IDYA)…

Ideaya Biosciences (IDYA) and GlaxoSmithKline (GSK) announced a strategic partnership in Synthetic Lethality. The strategic partnership includes Ideaya's Synthetic Lethality programs MAT2A, Pol Theta, and Werner Helicase programs, which are projected to reach clinical trials within the next three years. Ideaya has solved the crystal structures for each of its MAT2A, Pol Theta and Werner Helicase programs, enabling structure-based drug design, and has demonstrated in vivo proof of concept in relevant animal models for its MAT2A and Pol Theta programs. Synthetic Lethality is one of four core research focus areas for GSK in oncology. In synthetic lethality, cells tolerate the loss of single genes in isolation but not together in combination. When tumor suppressor genes are functionally lost in cancer, this mode of action can be used to exploit tumor-specific vulnerabilities through new medicines for patients with cancer. Ideaya will lead the MAT2A program through early clinical development. Ideaya is responsible for all costs of the MAT2A program prior to the GSK option exercise. Thereafter, Ideaya is responsible for 20% of global development costs. Ideaya will receive a 50% U.S. profit share and ex-U.S. royalties for the MAT2A and Werner Helicase programs and is responsible for 20% of global development costs for licensed products being developed with GSK. Ideaya will receive global royalties for the Pol Theta program, and GSK will cover all research, development, and commercialization costs. GSK will be responsible for all commercialization activities and costs globally for licensed products. The collaboration agreement is conditional upon customary conditions including regulatory review by the appropriate regulatory agencies under the Hart-Scott-Rodino Act.

ShowHide Related Items >><<
IDYA Ideaya Biosciences
$8.99 /

+1 (+12.52%)

GSK GlaxoSmithKline
$40.73 /

+0.305 (+0.75%)

IDYA Ideaya Biosciences
$8.99 /

+1 (+12.52%)

04/06/20
Fly Intel: Top five analyst initiations
04/06/20 H.C. Wainwright
Ideaya Biosciences initiated with a Buy at H.C. Wainwright
03/13/20
Fly Intel: Top analyst initiations
03/13/20 Roth Capital
Ideaya Biosciences initiated with a Buy at Roth Capital
GSK GlaxoSmithKline
$40.73 /

+0.305 (+0.75%)

05/14/20 UBS
GlaxoSmithKline price target raised to 1,920 GBp from 1,900 GBp at UBS
05/05/20 JPMorgan
GlaxoSmithKline price target lowered to 1,700 GBp from 1,750 GBp at JPMorgan
04/30/20 Barclays
GlaxoSmithKline price target raised to 1,550 GBp from 1,450 GBp at Barclays
03/11/20 JPMorgan
JPMorgan backs Neutral on GSK after 2019 annual report
IDYA Ideaya Biosciences
$8.99 /

+1 (+12.52%)

GSK GlaxoSmithKline
$40.73 /

+0.305 (+0.75%)

GSK GlaxoSmithKline
$40.73 /

+0.305 (+0.75%)

IDYA Ideaya Biosciences
$8.99 /

+1 (+12.52%)

GSK GlaxoSmithKline
$40.73 /

+0.305 (+0.75%)

GSK GlaxoSmithKline
$40.73 /

+0.305 (+0.75%)

Over a month ago
On The Fly
Fly Intel: After-Hours Movers » 19:07
06/01/20
06/01
19:07
06/01/20
19:07
NTLA

Intellia Therapeutics

$20.94 /

+3.43 (+19.59%)

, IDYA

Ideaya Biosciences

$10.80 /

+1.03 (+10.54%)

, INVH

Invitation Homes

$27.95 /

+1.64 (+6.23%)

, OSUR

OraSure

$14.12 /

-0.48 (-3.29%)

, ENS

EnerSys

$65.32 /

+1.9 (+3.00%)

, CSWC

Capital Southwest

$14.92 /

+0.935 (+6.69%)

, SALM

Salem Media

$0.99 /

+0.0935 (+10.45%)

, PUMP

ProPetro Holding

$5.00 /

+0.05 (+1.01%)

, PRCP

Perceptron

$3.09 /

+0.1 (+3.34%)

, WU

Western Union

$20.75 /

+0.72 (+3.59%)

, MGI

MoneyGram

$2.60 /

+0.185 (+7.66%)

Check out this evening's…

Open Full Text

ShowHide Related Items >><<
WU Western Union
$20.75 /

+0.72 (+3.59%)

SALM Salem Media
$0.99 /

+0.0935 (+10.45%)

PUMP ProPetro Holding
$5.00 /

+0.05 (+1.01%)

PRCP Perceptron
$3.09 /

+0.1 (+3.34%)

OSUR OraSure
$14.12 /

-0.48 (-3.29%)

NTLA Intellia Therapeutics
$20.94 /

+3.43 (+19.59%)

MGI MoneyGram
$2.60 /

+0.185 (+7.66%)

INVH Invitation Homes
$27.95 /

+1.64 (+6.23%)

IDYA Ideaya Biosciences
$10.80 /

+1.03 (+10.54%)

ENS EnerSys
$65.32 /

+1.9 (+3.00%)

CSWC Capital Southwest
$14.92 /

+0.935 (+6.69%)

NTLA Intellia Therapeutics
$20.94 /

+3.43 (+19.59%)

06/01/20 Wedbush
Intellia Therapeutics price target raised to $20 from $16 at Wedbush
02/28/20 Oppenheimer
Intellia making progress in in-vivo editing, says Oppenheimer
02/14/20 Wedbush
Intellia Therapeutics downgraded to Neutral from Outperform at Wedbush
02/14/20 Wedbush
Intellia Therapeutics downgraded to Neutral from Outperform at Wedbush
IDYA Ideaya Biosciences
$10.80 /

+1.03 (+10.54%)

04/06/20
Fly Intel: Top five analyst initiations
04/06/20 H.C. Wainwright
Ideaya Biosciences initiated with a Buy at H.C. Wainwright
03/13/20
Fly Intel: Top analyst initiations
03/13/20 Roth Capital
Ideaya Biosciences initiated with a Buy at Roth Capital
INVH Invitation Homes
$27.95 /

+1.64 (+6.23%)

06/01/20 Mizuho
Invitation Homes price target raised to $28 from $25 at Mizuho
05/14/20 RBC Capital
Invitation Homes price target lowered to $29 from $31 at RBC Capital
04/29/20 Credit Suisse
Invitation Homes price target lowered to $27 from $32 at Credit Suisse
04/29/20 Mizuho
Invitation Homes upgraded to Buy on relative valuation at Mizuho
OSUR OraSure
$14.12 /

-0.48 (-3.29%)

04/21/20 Stephens
OraSure resumed with an Equal Weight at Stephens
ENS EnerSys
$65.32 /

+1.9 (+3.00%)

04/02/20 Oppenheimer
EnerSys price target lowered to $75 from $80 at Oppenheimer
CSWC Capital Southwest
$14.92 /

+0.935 (+6.69%)

03/17/20 National Securities
Capital Southwest upgraded to Buy from Neutral at National Securities
03/03/20 National Securities
Capital Southwest downgraded to Neutral from Buy at National Securities
12/12/19 Raymond James
Capital Southwest initiated with an Outperform at Raymond James
12/12/19 Raymond James
Capital Southwest initiated with an Outperform at Raymond James
SALM Salem Media
$0.99 /

+0.0935 (+10.45%)

PUMP ProPetro Holding
$5.00 /

+0.05 (+1.01%)

03/25/20 JPMorgan
Liberty Oilfield Services downgraded to Neutral with $5 target at JPMorgan
03/19/20 Wolfe Research
ProPetro Holding downgraded to Peer Perform from Outperform at Wolfe Research
03/19/20 Barclays
ProPetro Holding downgraded to Equal Weight from Overweight at Barclays
03/17/20 B. Riley FBR
B. Riley FBR says be 'highly selective' in Oilfield Services, downgrades three
PRCP Perceptron
$3.09 /

+0.1 (+3.34%)

03/19/20 B. Riley FBR
B. Riley FBR downgrades four names with exposure to auto manufacturers
03/19/20 B. Riley FBR
Perceptron downgraded to Neutral from Buy at B. Riley FBR
WU Western Union
$20.75 /

+0.72 (+3.59%)

04/08/20 Wells Fargo
Western Union downgraded to Underweight from Equal Weight at Wells Fargo
04/06/20 Barclays
Western Union price target lowered to $18 from $25 at Barclays
04/03/20 Northcoast
Northcoast cuts estimates for MoneyGram and Western Union
04/02/20 SunTrust
Western Union price target lowered to $18 from $27 at SunTrust
MGI MoneyGram
$2.60 /

+0.185 (+7.66%)

04/06/20 Barclays
MoneyGram price target lowered to $1 from $2 at Barclays
03/24/20 Northland
Northland downgrades MoneyGram to Market Perform on coronavirus lockdowns
03/24/20 Northland
MoneyGram downgraded to Market Perform from Outperform at Northland
WU Western Union
$20.75 /

+0.72 (+3.59%)

SALM Salem Media
$0.99 /

+0.0935 (+10.45%)

PUMP ProPetro Holding
$5.00 /

+0.05 (+1.01%)

PRCP Perceptron
$3.09 /

+0.1 (+3.34%)

OSUR OraSure
$14.12 /

-0.48 (-3.29%)

NTLA Intellia Therapeutics
$20.94 /

+3.43 (+19.59%)

MGI MoneyGram
$2.60 /

+0.185 (+7.66%)

INVH Invitation Homes
$27.95 /

+1.64 (+6.23%)

IDYA Ideaya Biosciences
$10.80 /

+1.03 (+10.54%)

ENS EnerSys
$65.32 /

+1.9 (+3.00%)

CSWC Capital Southwest
$14.92 /

+0.935 (+6.69%)

  • 03
    Jun
  • 03
    Jun
  • 02
    Jun
WU Western Union
$20.75 /

+0.72 (+3.59%)

PUMP ProPetro Holding
$5.00 /

+0.05 (+1.01%)

INVH Invitation Homes
$27.95 /

+1.64 (+6.23%)

PUMP ProPetro Holding
$5.00 /

+0.05 (+1.01%)

INVH Invitation Homes
$27.95 /

+1.64 (+6.23%)

WU Western Union
$20.75 /

+0.72 (+3.59%)

PUMP ProPetro Holding
$5.00 /

+0.05 (+1.01%)

MGI MoneyGram
$2.60 /

+0.185 (+7.66%)

ENS EnerSys
$65.32 /

+1.9 (+3.00%)

CSWC Capital Southwest
$14.92 /

+0.935 (+6.69%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.